Daily high-dose aspirin taken for at least 2 years reduces the risk of colorectal cancer but not other cancers in people with Lynch syndrome

Questions To Ask Your Health Care Provider

• Should I take a daily aspirin to reduce my colon cancer risk?
• What are the benefits and risks of taking a daily aspirin to reduce my colon cancer risk?
• What dose and for how long should I take a daily aspirin to reduce my colon cancer risk?
• What other ways can I reduce my risk of Lynch syndrome-associated cancers?

Open Clinical Trials

The following screening and prevention studies are open to people with Lynch syndrome. 

Colorectal cancer

• NCT03831698: Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE). This study assesses the effects of omega-3 acid ethyl esters capsules (generic Lovaza) on molecular and intestinal microbiota changes in participants at high risk for colorectal cancer.
• NCT04379999: Atorvastatin ± Aspirin in Lynch Syndrome Syndrome. This study investigates whether a common cholesterol-lowering agent (atorvastatin) alone or combined with a nonsteroidal anti-inflammatory drug (aspirin) reduces the risk of colorectal cancer in high-risk individuals with Lynch syndrome.

Gynecologic cancers

• NCT05257057: Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome. This study examines endometrial hyperplasia specimens and compares the frequency of Lynch syndrome gene mutations between people with endometrial hyperplasia and those with endometrial cancer. 
• NCT00508573: Registry for Women Who Are At Risk Or May Have Lynch Syndrome. This study facilitates the study of gynecologic cancer risks by creating a registry of information about women who have or are at risk for Lynch syndrome, to facilitate study of gynecologic cancer risks.
• Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE). The goal of this effort is to develop a clinical diagnostic test to detect early-onset ovarian cancer, as currently, no reliable screening or early-detection tests are available.

Prostate cancer

• NCT03805919: Men at High Genetic Risk for Prostate Cancer. This is a prostate cancer screening study using MRI in high-risk men is open to men with Lynch syndrome and other mutations.
• NCT05129605: Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS).  This study looks at how well prostate MRI works as a screening tool for men at high risk for prostate cancer. Enrollment is open to men with an inherited mutation in ATM, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53 and other genes. 

Pancreatic cancer

• NCT02206360: Pancreatic Cancer Early Detection Program. This pancreatic cancer screening study uses esophageal ultrasound to screen for pancreatic cancer in high-risk people. The study is open to people who have a family history of pancreatic cancer and an MLH1 mutation or other mutation linked to increased cancer risk.
• NCT03568630: Blood Markers of Early Pancreas Cancer. This pancreatic cancer study involves blood samples taken over time to identify biomarkers of pancreatic cancer in high-risk people. Enrollment is open to people with an MLH1 mutation or other mutation linked to increased cancer risk.
• NCT03250078: A Pancreatic Cancer Screening Study in Hereditary High-Risk Individuals. The main goal of this study is to screen and detect pancreatic cancer and precursor lesions in individuals with a strong family history or genetic predisposition to pancreatic cancer. MRI and magnetic cholangiopancreatography (MRI/MRCP) will be utilized to screen for early-stage pancreatic lesions.

Other clinical trials for patients with endometrial cancer can be found here.